Clinical Trials News

NATICK, Mass.--(BUSINESS WIRE)--AutoIVF, a fertility technology company developing automated solutions for reproductive medicine, today announced the publication of a peer-reviewed clinical study in Nature Medicine describing the recovery of additional oocytes from discarded follicular fluid following standard clinical screening using the company’s automated egg-recovery technology, OvaReady™. The study evaluated follicular fluid samples from 582 patients across four accredited in vitro fertili...

ESSEX, Conn.--(BUSINESS WIRE)--Thetis Pharmaceuticals, LLC ("Thetis"), a clinical-stage company developing TP-317, a first-in-class, oral BLT1 agonist for inflammatory bowel disease (IBD) and cancer, today announced the appointment of four distinguished clinician-scientists to its IBD Scientific Advisory Board (SAB): Silvio Danese, MD, PhD; Laurent Peyrin-Biroulet, MD, PhD; Walter Reinisch, MD; and Bram Verstockt, MD, PhD. The new SAB members are internationally recognized leaders in gastroente...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--SURGE Therapeutics Completes Phase 1 Dosing of First-in-Category Intraoperative Immunotherapy and Prepares for Registrational Trial...

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on February 26, 2026, at 8:30 AM Eastern Time to discuss results for its fourth quarter and full year ended December 31, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Th...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2025 and reviewed recent business highlights. “2025 was a year of key accomplishments for Alnylam, highlighted by the landmark approval of AMVUTTRA for ATTR-CM in the U.S., which drove total net product revenues of nearly $3 billion, or 81% growth year-over-year, and prope...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Iterative Health announced the appointment of Nadege Gunn, MD, CPI, DABOM, FAASLD, as Chief Medical Officer, Hepatology and Obesity....

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Friday, February 27, 2026. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the result...

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of three abstracts for presentation at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting taking place in Philadelphia, Pennsylvania from February 27–March 2, 2026. The following poster presentations will take place on Friday, February 27 from 2:45–3:45 pm ET in the Convention Center, Level 2, Hall E: Response Drivers in Sebetral...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS), the world's leading animal health company, today reported its financial results for the fourth quarter and full year 2025 and provided full year guidance for 2026. The company reported revenue of $2.4 billion for the fourth quarter of 2025, an increase of 3% compared with the fourth quarter of 2024. On an organic operational1 basis, revenue for the fourth quarter of 2025 increased 4% compared with the fourth quarter of 2024. Net income...

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that the first participant has been dosed in BASECAMP, a three-month, randomized, double-blind, placebo-controlled, proof-of-concept, Phase 2 pediatric study of SAT-3247 for Duchenne muscular dystrophy (“Duchenne” or “DMD”). The study will evaluate SAT-3247 in...